jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2012-4-4-46-51jofin-132Research ArticleОригинальные исследованияOriginal ResearchМАРКЕРЫ АКТИВАЦИИ ЭНДОТЕЛИЯ СОСУДОВ (VCAM-1, VWF) У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЕПАТИТОМ С С ИНСУЛИНОРЕЗИСТЕНТНОСТЬЮEndothelial activation markers (VCAM-1, vWF) in patients with chronic hepatitis C and insulin resistanceАнтоноваТ. В.AntonovaT. V.

профессор кафедры инфекционных болезней и эпидемиологии с курсом ВИЧ-медицины Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова, ведущий научный сотрудник группы инфекционных патологий Федерального центра сердца, крови и эндокринологии имени В.А. Алмазова, д.м.н, профессор; тел. (812)499-70-58

infection@spmu.rssi.ruРомановаМ. А.RomanovaM. A.

ассистент кафедры инфекционных болезней и эпидемиологии с курсом ВИЧ-медицины Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова, к.м.н.; тел. (812)499-70-58

mromanova81@mail.ruЛымарьЮ. В.LymarYu. V.

научный сотрудник отделения инфекционной патологии Федерального центра сердца, крови и эндокринологии имени В.А. Алмазова

yulikdoctor@mail.ruСанкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, Санкт-Петербург Федеральный центр сердца, крови и эндокринологии имени В.А. Алмазова, Санкт-ПетербургРоссияSaint-Petersburg State Medical University named after academic I.P. Pavlov, Saint-Petersburg Federal Centre of Heart, Blood and Endocrinology named after V.A. Almazov, Saint-PetersburgRussian FederationСанкт-Петербургский государственный медицинский университет имени академика И.П. Павлова, Санкт-ПетербургРоссияSaint-Petersburg State Medical University named after academic I.P. Pavlov, Saint-PetersburgRussian FederationФедеральный центр сердца, крови и эндокринологии имени В.А. Алмазова, Санкт-ПетербургРоссияFederal Centre of Heart, Blood and Endocrinology named after V.A. Almazov, Saint-PetersburgRussian Federation201215092014444651Copyright © Антонова Т.В., Романова М.А., Лымарь Ю.В., 20142014Антонова Т.В., Романова М.А., Лымарь Ю.В.Antonova T.V., Romanova M.A., Lymar Y.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/132

Проведена оценка содержания в крови маркеров активации эндотелия (sVCAM-1, vWF:Ag) у больных хроническим гепатитом С при наличии инсулинорезистентности, метаболического синдрома и его компонентов. В исследование включено 69 больных хроническим гепатитом С с малосимптомным течением заболевания. У каждого третьего пациента (33,3%) выявлено повышение в крови содержания sVCAM-1 и/или vWF:Ag. У больных хроническим гепатитом С с инсулинорезистентностью, метаболическим синдромом существенно чаще обнаружены признаки адгезионной дисфункции эндотелия (повышение концентрации в крови sVCAM-1), чем у пациентов без этих нарушений. Установлено, что при выраженном фиброзе печени концентрация в крови sVCAM-1 значительно выше по сравнению с показателями у пациентов с начальными стадиями фиброза (F0–F2), в том числе и среди больных  без инсулинорезистентности. Эти данные позволяют говорить о многофакторном развитии дисфункции эндотелия при хроническом гепатите С.

Blood markers of endothelial activation (sVCAM-1, vWF: Ag) in patients with chronic hepatitis C in the presence of insulin resistance, metabolic syndrome and its components had been evaluated. The study included 69 patients with chronic hepatitis C with oligosymptomatic the disease. In one third of cases of chronic hepatitis C (33.3%) showed improvement in the blood content of sVCAM-1 and / or vWF: Ag. In patients with chronic hepatitis C with insulin resistance, metabolic syndrome significantly more often found signs adhesion of endothelial dysfunction (increased blood concentrations of sVCAM-1) than in patients without these disorders. Found that in patients with severe hepatic fibrosis in patients with chronic hepatitis C blood concentration sVCAM-1 is significantly higher compared to patients with early stages of fibrosis (F0-F2), including those in patients without insulin resistance. These data suggest the multivariate development of endothelial dysfunction in chronic hepatitis C.

хронический гепатит Синсулино-резистентностьмолекула сосудистой клеточной адгезии-1фактор Виллебрандтаchronic hepatitis Cinsulin resistancevascular cellular adhesion molecule-1von Willebrand factorReferencesGiron-Gonzalez, J.A. Serial analysis of serum and ascitic fluid levels of soluble adhesion molecules and chemokines in patients with spontaneous bacterial peritonitis / J.A.Giron- Gonzalez [et al.] // Clin. Exp. Immunol. – 2001. – V. 123, № 1. – P. 56–61.Giron-Gonzalez, J.A. Serial analysis of serum and ascitic fluid levels of soluble adhesion molecules and chemokines in patients with spontaneous bacterial peritonitis / J.A.Giron- Gonzalez [et al.] // Clin. Exp. Immunol. – 2001. – V. 123, № 1. – P. 56–61.Thomson, A.W. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes / A.W. Thomson [et al.] // Clin. Exp. Immunol. – 1994. – V. 95, № 1. – P. 83–90.Thomson, A.W. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated human hepatocytes / A.W. Thomson [et al.] // Clin. Exp. Immunol. – 1994. – V. 95, № 1. – P. 83–90.Tortorella, C. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology / C. Tortorella [et al.] // Immunopharmacol Immunotoxicol. – 2000. – V. 22, № 1. – P. 19–33.Tortorella, C. sICAM-1, sCD95 and sCD95L levels in chronic liver diseases of different etiology / C. Tortorella [et al.] // Immunopharmacol Immunotoxicol. – 2000. – V. 22, № 1. – P. 19–33.de Caestecker, J.S. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis / J.S. de Caestecker // Eur. J. Gastroenterol. Hepatol. – 1997. – V. 9, № 2. – P. 145–147.de Caestecker, J.S. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis / J.S. de Caestecker // Eur. J. Gastroenterol. Hepatol. – 1997. – V. 9, № 2. – P. 145–147.Granot, E. Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients / E. Granot, D. Shouval, Y. Ashur // Mediators Inflamm. – 2001. – V. 10, № 5. – P. 253–258.Granot, E. Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients / E. Granot, D. Shouval, Y. Ashur // Mediators Inflamm. – 2001. – V. 10, № 5. – P. 253–258.Marui, A. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon / A. Marui [et al.] // J. Int. Med. Res. – 1996. – V. 24, № 3. – P. 258–265.Marui, A. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon / A. Marui [et al.] // J. Int. Med. Res. – 1996. – V. 24, № 3. – P. 258–265.Kukla, M. sPECAM-1 and sVCAM-1: Role in Pathogenesis and Diagnosis of Chronic Hepatitis C and Association with Response to Antiviral Therapy / M. Kukla [et al.] // Therap. Adv. Gastroenterol. – 2009. – V. 2, № 2. – P. 79–90.Kukla, M. sPECAM-1 and sVCAM-1: Role in Pathogenesis and Diagnosis of Chronic Hepatitis C and Association with Response to Antiviral Therapy / M. Kukla [et al.] // Therap. Adv. Gastroenterol. – 2009. – V. 2, № 2. – P. 79–90.Петрищев, Н.Н. Типовые формы дисфункции эндотелия / Н.Н. Петрищев [и др.] // Клин. лаб. консилиум. – 2007. – № 18. – С. 31–35.Петрищев, Н.Н. Типовые формы дисфункции эндотелия / Н.Н. Петрищев [и др.] // Клин. лаб. консилиум. – 2007. – № 18. – С. 31–35.Ley, K. VCAM–1 is critical in atherosclerosis / K. Ley, Y. Huo // J. Clin. Invest. – 2001. – № 107 (10). – P. 1209–1210.Ley, K. VCAM–1 is critical in atherosclerosis / K. Ley, Y. Huo // J. Clin. Invest. – 2001. – № 107 (10). – P. 1209–1210.Blann, A.D. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease /A.D. Blann // J. Reumatol. – 1993. – № 20. – P. 1469–1471.Blann, A.D. Von Willebrand factor as a marker of injury to the endothelium in inflammatory vascular disease /A.D. Blann // J. Reumatol. – 1993. – № 20. – P. 1469–1471.Булатова, И.А. Функциональное состояние эндотелия при хроническом гепатите С / И.А. Булатова, В.В. Щёкотов, А.П. Щёкотова // РЖГГК. – 2009. – Т. 3. – С. 42–46.Булатова, И.А. Функциональное состояние эндотелия при хроническом гепатите С / И.А. Булатова, В.В. Щёкотов, А.П. Щёкотова // РЖГГК. – 2009. – Т. 3. – С. 42–46.Kulwas, A. Von Willebrand factor and thrombomodulin as markers of endothelial cell functions in children with chronic viral hepatitis / A. Kulwas [et al.] // Med. Wieku Rozwoj. – 2004. – V. 8, № 1. – P. 107–114.Kulwas, A. Von Willebrand factor and thrombomodulin as markers of endothelial cell functions in children with chronic viral hepatitis / A. Kulwas [et al.] // Med. Wieku Rozwoj. – 2004. – V. 8, № 1. – P. 107–114.Hui, J. Insulin resistance is associated with chronic hepatitis C and fibrosis progression / J. Hui [et al.] // Gastroenterology. – 2003. – V. 125, № 6. – P. 1695–1704.Hui, J. Insulin resistance is associated with chronic hepatitis C and fibrosis progression / J. Hui [et al.] // Gastroenterology. – 2003. – V. 125, № 6. – P. 1695–1704.D’Sousa, R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy / R. D’Sousa, A. Sabin, G. R. Foster // Am. J. Gastroenterol. – 2005. – V. 100. – P. 1509–1515.D’Sousa, R. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy / R. D’Sousa, A. Sabin, G. R. Foster // Am. J. Gastroenterol. – 2005. – V. 100. – P. 1509–1515.Cersosimo, E. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases / E. Cersosimo, R.A. DeFronzo // Diabetes Metab Res Rev. – 2006. – V. 22, № 6. – P. 423–436.Cersosimo, E. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases / E. Cersosimo, R.A. DeFronzo // Diabetes Metab Res Rev. – 2006. – V. 22, № 6. – P. 423–436.Hsueh, W.A. Insulin resistance and the endothelium /W.A. Hsueh, C.J. Lyon, M.J. Quiñones // Am, J, Med. –2004. – V. 117, № 2. – P. 109–117.Hsueh, W.A. Insulin resistance and the endothelium /W.A. Hsueh, C.J. Lyon, M.J. Quiñones // Am, J, Med. –2004. – V. 117, № 2. – P. 109–117.Bruno, C.M. Circulating adhesion molecules in patients with virus-related chronic diseases of the liver / C.M. Bruno [et al.] // World J. Gastroenterol. – 2005. – V. 11, № 29. – P. 4566–4569.Bruno, C.M. Circulating adhesion molecules in patients with virus-related chronic diseases of the liver / C.M. Bruno [et al.] // World J. Gastroenterol. – 2005. – V. 11, № 29. – P. 4566–4569.Lo Iacono, O. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha / O. Lo Iacono [et al.] // Aliment Pharmacol Ther. – 1998. – V. 12, № 11. – P. 1091–1099.Lo Iacono, O. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha / O. Lo Iacono [et al.] // Aliment Pharmacol Ther. – 1998. – V. 12, № 11. – P. 1091–1099.Fukuda, Y. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus / Y. Fukuda [et al.] // J. Int. Med. Res. – 1998. – V. 26, № 6. – P. 313–318.Fukuda, Y. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in asymptomatic carriers of hepatitis C virus / Y. Fukuda [et al.] // J. Int. Med. Res. – 1998. – V. 26, № 6. – P. 313–318.La Mura, V. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension /V. La Mura [et al.] // Gut. – 2011. – V. 60, № 8. – P. 1133– 1138.La Mura, V. Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension /V. La Mura [et al.] // Gut. – 2011. – V. 60, № 8. – P. 1133– 1138.Ferlitsch, M. Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis / M. Ferlitsch [et al.] // Hepatology. – 2012. – V. 56, № 4. – P. 1439–1447.Ferlitsch, M. Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis / M. Ferlitsch [et al.] // Hepatology. – 2012. – V. 56, № 4. – P. 1439–1447.

The authors declare that there are no conflicts of interest present.